Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands.
Institute for Clinical Chemistry and Laboratory Medicine, University Hospital and Faculty of Medicine, TU Dresden, Dresden, Germany.
Front Immunol. 2024 Feb 13;15:1323333. doi: 10.3389/fimmu.2024.1323333. eCollection 2024.
cell wall component β-glucan has been extensively studied for its ability to induce epigenetic and functional reprogramming of innate immune cells, a process termed . We show that a high-complexity blend of two individual β-glucans from possesses strong bioactivity, resulting in an enhanced trained innate immune response by human primary monocytes. The training required the Dectin-1/CR3, TLR4, and MMR receptors, as well as the Raf-1, Syk, and PI3K downstream signaling molecules. By activating multiple receptors and downstream signaling pathways, the components of this β-glucan preparation are able to act synergistically, causing a robust secondary response upon an unrelated challenge. In murine models of melanoma and bladder cell carcinoma, pre-treatment of mice with the β-glucan preparation led to a significant reduction in tumor growth. These insights may aid in the development of future therapies based on β-glucan structures that induce an effective trained immunity response.
细胞壁成分β-葡聚糖因其能够诱导先天免疫细胞的表观遗传和功能重编程而被广泛研究,这一过程称为训练性免疫。我们表明,两种来自 的个体β-葡聚糖的高复杂度混合物具有很强的生物活性,导致人类原代单核细胞增强了训练有素的先天免疫反应。这种训练需要 Dectin-1/CR3、TLR4 和 MMR 受体,以及 Raf-1、Syk 和 PI3K 下游信号分子。通过激活多个受体和下游信号通路,这种β-葡聚糖制剂的成分能够协同作用,在受到无关挑战时引起强烈的二次反应。在黑色素瘤和膀胱癌的 小鼠模型中,用该β-葡聚糖制剂预处理小鼠可显著减少肿瘤生长。这些见解可能有助于基于诱导有效训练性免疫反应的β-葡聚糖结构开发未来的治疗方法。